Monday, May 19, 2008

U.S. Food & Drug Administration (FDA) Daily Digest Bulletin

Updates : 1

From: "U.S. Food & Drug Administration (FDA)" <fda@service.govdelivery.com>
Date: Fri, 16 May 2008 06:08:24 -0500 (CDT)
Subject: CDRH New Update

Skip NavigationFDA Logo links to FDA home pageCenter for Devices and Radiological Health, U.S. Food and Drug AdministrationHHS Logo links to Department of Health and Human Services website

FDA Home Page | CDRH Home Page | Search | A-Z Index U.S. Food and Drug AdministrationCenter for Devices and Radiological Health Questions?
horizonal rule
CDRHNEW Logo Date: May 16, 2008

The following new items were added to the CDRH web pages on May 15, 2008. Previous CDRH New Items can be found on the CDRHNew Page.

* Inspection of Domestic and Foreign Manufacturers of Diagnostic X Ray Equipment Text

---


Updates: 2
From: "U.S. Food & Drug Administration (FDA)" <fda@service.govdelivery.com>
Date: Fri, 16 May 2008 09:05:16 -0500 (CDT)
Subject: FDA Shuts Down Seafood Processing Company, Requires Products Be Recalled

FDA Shuts Down Seafood Processing Company, Requires Products Be Recalled
Fri, 16 May 2008 08:31:00 -0500

The U.S. Food and Drug Administration today directed Hope Food Supply Inc., a Pasadena, Texas, food processing company, to shut down and immediately recall all products manufactured from its Texas facility since 2007.


Updates: 3
From: "U.S. Food & Drug Administration (FDA)" <fda@service.govdelivery.com>
Date: Fri, 16 May 2008 09:05:21 -0500 (CDT)
Subject: FDA Shuts Down Seafood Processing Company, Requires Products Be Recalled (May 16)

FDA Shuts Down Seafood Processing Company, Requires Products Be Recalled (May 16)
Fri, 16 May 2008 08:44:00 -0500

The U.S. Food and Drug Administration directed Hope Food Supply Inc., a Pasadena, Texas, food processing company, to shut down and immediately recall all products manufactured from its Texas facility since 2007.


Updates: 4
From: "U.S. Food & Drug Administration (FDA)" <fda@service.govdelivery.com>
Date: Fri, 16 May 2008 09:05:49 -0500 (CDT)
Subject: FDA Obtains Permanent Injunction Against Scientific Laboratories, Inc.

FDA Obtains Permanent Injunction Against Scientific Laboratories, Inc.
Fri, 16 May 2008 08:31:00 -0500

The U.S. Food and Drug Administration (FDA) today announced that Scientific Laboratories Inc., and its president, Rajeshwari Patel, and chief executive officer, Amit Roy, have signed a Consent Decree of Permanent Injunction and are barred from manufacturing and distributing drug products until they bring their manufacturing operations into compliance with law and obtain approval for their products.


Updates: 5
From: "U.S. Food & Drug Administration (FDA)" <fda@service.govdelivery.com>
Date: Fri, 16 May 2008 15:06:50 -0500 (CDT)
Subject: FDA & You Survey - We Would Like to Hear From You

Dear FDA & YOU Reader,

Now's your chance to tell us what you think. Take our short, five-minute survey at https://www.surveymonkey.com/s.aspx?sm=vHKLw0XNppujvE2pxFTOJQ_3d_3d.

Your responses will help us improve FDA & YOU. Your participation is completely voluntary and your responses will not have an effect on your eligibility for receipt of any FDA services. All responses will be anonymous.

We look forward to hearing from you!

The FDA & YOU Team

You are subscribed to FDA & You for U.S. Food & Drug Administration (FDA). This information has recently been updated, and is now available.


Updates: 6
From: "U.S. Food & Drug Administration (FDA)" <fda@service.govdelivery.com>
Date: Fri, 16 May 2008 16:15:39 -0500 (CDT)
Subject: Bayer Removes Remaining Trasylol Stock

Bayer Removes Remaining Trasylol Stock
Fri, 16 May 2008 15:45:00 -0500

Bayer will begin removing the remaining Trasylol, a drug used to control bleeding during heart surgery, from the U.S. market.


Message: 7
From: "U.S. Food & Drug Administration (FDA)" <fda@service.govdelivery.com>
Date: Fri, 16 May 2008 16:15:48 -0500 (CDT)
Subject: Controlling Cholesterol with Statins

Controlling Cholesterol with Statins
Fri, 16 May 2008 15:45:00 -0500

When diet and exercise alone are not enough to reduce cholesterol to goal levels, doctors often prescribe statin medications. These drugs can reduce the risk of heart attack, stroke, and death.


Updates: 8
From: "U.S. Food & Drug Administration (FDA)" <fda@service.govdelivery.com>
Date: Fri, 16 May 2008 17:56:31 -0500 (CDT)
Subject: CDER New 5/15 & 16/2008

FDA Logo links to FDA home page
Center for Drug Evaluation and Research, U.S. Food and Drug Administration
HHS Logo links to Department of Health and Human Services website

CDERnew Logo

May 16, 2008

  • FDA issues an FDA Alert and Information for Healthcare Professional sheet for Mycophenolate Mofetil (marketed as CellCept) and Mycophenolic Acid (marketed as Myfortic). Drug Information.

May 15, 2008


Updates: 9
From: "U.S. Food & Drug Administration (FDA)" <fda@service.govdelivery.com>
Date: Fri, 16 May 2008 19:01:27 -0500 (CDT)
Subject: CDER New

FDA Logo links to FDA home page
Center for Drug Evaluation and Research, U.S. Food and Drug Administration
HHS Logo links to Department of Health and Human Services website

CDERnew Logo

May 16, 2008


Updates: 10
From: "U.S. Food & Drug Administration (FDA)" <fda@service.govdelivery.com>
Date: Fri, 16 May 2008 14:12:01 -0500 (CDT)
Subject: FDA MedWatch - FDA Alert and Healthcare Professional Information Sheet issued for Mycophenolate Mofetil (CellCept) and Mycophenolic Acid (Myfortic)

MedWatch logo MedWatch - The FDA Safety Information and Adverse Event Reporting Program

FDA is aware of reports of infants born with serious congenital anomalies, including microtia and cleft lip and palate, following exposure to mycophenolate mofetil (MMF) during pregnancy. MMF, the active drug substance in CellCept, is an ester of the active metabolite mycophenolic acid (MPA), the active drug substance in Myfortic. In most cases, the mothers were taking MMF following an organ transplant to prevent organ rejection. However, some mothers taking MMF were being treated for immune-mediated conditions such as systemic lupus erythematosus (SLE) and erythema multiforme. Treatment began before their pregnancies and continued into the first trimester or until the pregnancy was detected. MMF and MPA increase the risk of spontaneous abortion in the first trimester and can cause congenital malformations in the offspring of women who are treated during pregnancy.

FDA is continuing to work with the manufacturers of these drug products to develop and implement means to mitigate the risks of fetal exposure. See the FDA Healthcare Professional Information Sheet containing considerations and recommendations for clinicians prior to prescribing MMF or MPA to women of childbearing potential.

Read the entire 2008 MedWatch Safety Summary, including a link to the FDA Alert and Healthcare Professional Information Sheet regarding this issue at:

http://www.fda.gov/medwatch/safety/2008/safety08.htm#MMF



This service is provided to you at no charge by U.S. Food & Drug Administration (FDA).

GovDelivery, Inc. sending on behalf of U.S. Food & Drug Administration (FDA) · 5600 Fishers Lane · Rockville MD 20857 · 800-439-1420